anti-PD-L1 peptide

The anti-PD-L1 peptide is a peptide-based therapeutic candidate designed to block the Programmed Death-Ligand 1 (PD-L1) checkpoint. By inhibiting the interaction between PD-L1 and its receptor PD-1, the peptide aims to restore the anti-tumor activity of T cells. In preclinical research conducted at the University of Missouri-Kansas City, this peptide has been evaluated in combination with PCBP2 siRNA nanoparticles for the treatment of pancreatic ductal adenocarcinoma (PDAC). The combination strategy focuses on normalizing the dense tumor stroma by silencing the RNA binding protein αCP2 (encoded by PCBP2), which destabilizes type I collagen mRNA, thereby improving the infiltration of immune cells and the overall efficacy of the anti-PD-L1 immunotherapy.

Other names

anti-PD-L1 peptideanti-PD-L-1 peptideanti-PD-L 1 peptide